---
document_datetime: 2024-10-22 14:21:12
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/otezla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: otezla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.3950403
conversion_datetime: 2025-12-29 23:08:09.096829
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Otezla

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                          |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------|
| II/0044/G            | This was an application for a group of variations. Type II (C.I.6.a): Extension of indication to include the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years and weighing at least 20 kg who are candidates for | 19/09/2024                          | 21/10/2024                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion EMEA/H/C/003746/II/0044/G. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| systemic therapy, based CC-10004-PPSO-003 as CC-10004-PPSO-001 and 10004-PPSO-003 is a phase randomized, double-blind, to assess the efficacy and paediatric subjects from with moderate to severe consequence, sections of the SmPC are updated. updated in accordance. agreed. In addition, MAH introduce editorial changes line with the current QRD list of local representative Leaflet. 2 Type IA (B.II.e.5.a.1): 8 of the SmPC to introduce within approved range update (initiation pack 10 mg, 23 x 20 mg) and 20mg) in a pack size of C.I.6.a - Change(s) to therapeutic Addition of a new therapeutic modification of an approved B.II.e.5.a.1 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                |            |            |    |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| IAIN/0043/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site A.7 - Administrative change - Deletion of | 16/02/2023 | n/a        |    |                                   |
| IB/0042/G           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                       | 08/02/2023 | n/a        |    |                                   |
| PSUSA/10338 /202203 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                       | 27/10/2022 | n/a        |    | PRAC Recommendation - maintenance |
| N/0040              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                               | 13/07/2022 | 21/10/2024 | PL |                                   |
| II/0038             | C.I.13 - Submission of the final study report (CSR) from PsOBest Registry, listed as a category 3 study                                                                                                                                                                                                                                                        | 05/05/2022 | n/a        |    | n/a                               |

<div style=\"page-break-after: always\"></div>

|             | in the RMP. This is an observational study to assess the long-term safety and effectiveness of apremilast in routine clinical practice in Germany. The RMP version 14.1 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0039     | C.I.13- Submission of the final study report (CSR) from UK Clinical Practice Research Database (CPRD), listed as a category 3 study in the RMP. This is an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP version 14.1 is accepted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 07/04/2022 | n/a        | This variation concerns the final study reports of the post- authorization safety study 'Clinical Practice Research Datalink (CPRD) data analysis for psoriatic arthritis and psoriasis', listed as a category 3 study in the Risk Management Plan (RMP), to evaluate the risk of Adverse Events Special Interest (AESIs) in patients exposed to apremilast compared to a set of patients with psoriasis or psoriatic arthritis who received other treatments. Overall, the results do not suggest any new safety concerns for Apremilast and are in line with the known safety profile. However, the study has several limitations concerning quality and completeness of data from CPRD Aurum, low sample size, and unadjusted study outcomes that do not allow to reach robust conclusions. |
| N/0037      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                              | 09/07/2021 | 21/10/2024 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0036/G | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                               | 30/04/2021 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|             | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                 |              |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------|
| IB/0034/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or of a novel excipient | 14/04/2021 | 21/06/2021 | Annex II and PL | manufacturer |
| IAIN/0033/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - or addition of a manufacturer                                                                                                                                                                 | 24/06/2020 | 21/06/2021 | Annex II and PL | Replacement  |

<div style=\"page-break-after: always\"></div>

|                     | responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                         |            |            |                        |                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                 | 27/02/2020 | 08/04/2020 | SmPC and PL            | Please refer to Scientific Discussion Otezla- EMEA/H/C/003746 -II-0029                                                                                                                                                                                                |
| T/0032              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                            | 07/01/2020 | 31/01/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                       |
| IB/0031             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                      | 18/10/2019 | 31/01/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                       |
| PSUSA/10338 /201903 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                       | 03/10/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                        | 27/06/2019 | 23/08/2019 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Otezla in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| N/0030              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                               | 31/07/2019 | 31/01/2020 | Labelling and PL       |                                                                                                                                                                                                                                                                       |
| II/0023             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 14/06/2019 | n/a        |                        |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IA/0026             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/03/2019   | 23/08/2019   | Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0025             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20/02/2019   | n/a          |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| PSUSA/10338 /201803 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/10/2018   | 18/12/2018   | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10338/201803.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0021             | Update of sections 4.2 and 5.1 of Otezla SmPC with information up to 5 years of treatment following the long-term extension phases of 2 pivotal Phase 3 studies of apremilast in the treatment of moderate to severe plaque psoriasis and 3 pivotal and 1 supportive Phase 3 studies in the treatment of active psoriatic arthritis (CC-10004-PSA-002, -003, -004, - 005 and CC-10004-PSOR-008, - 009) listed as a category 3 study in the RMP (MEA 002) C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 08/11/2018   | 23/08/2019   | SmPC              | In psoriatic arthritis patients, ACR responses were maintained in the long-term open label extension studies for up to 5 years. The clinical responses were maintained in the same parameters of peripheral activity and in the skin manifestations of psoriasis in the open-label extension studies for up to 5 years of treatment. Improved physical function as assessed by the HAQ-DI and the SF36v2PF domain, and the FACIT-fatigue scores were maintained in the open-label extension studies for up to 5 years of treatment. In psoriasis patients, improvements were generally maintained in PASI score, affected BSA, itch, nail and quality of life measures for up to 5 years. The long-term safety of apremilast 30 mg twice daily in patients with psoriatic arthritis and psoriasis in open-label extension studies for a total duration of treatment up to 5 |
| IAIN/0024/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/10/2018   | 18/12/2018   | Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |            |                        |                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0020  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29/06/2018 | 02/08/2018 | SmPC, Labelling and PL |                                                                                                                                                                 |
| IA/0022 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                           | 01/08/2018 | n/a        |                        |                                                                                                                                                                 |
| II/0018 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                | 08/03/2018 | n/a        |                        |                                                                                                                                                                 |
| II/0017 | Update of section 4.4 and 4.8 of the SmPC to include a warning on severe diarrhoea, nausea, and vomiting following a safety cumulative review of all data                                                                                                                                                                                                                                                                                                                                                                     | 09/11/2017 | 02/08/2018 | SmPC, Labelling and PL | The Product Information has been updated with the inclusion of wording in the SmPC to describe that there have been post-marketing reports of severe diarrhoea, |

<div style=\"page-break-after: always\"></div>

|                     | sources. The PL has been updated accordingly. In addition the MAH took the opportunity to introduce editorial changes in Annex IIIA and to align the PI with QRD template 10.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                        |            |     | nausea, and vomiting associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications. Patients who reduced dosage or discontinued Otezla generally improved quickly. If patients develop severe diarrhoea, nausea, or vomiting, discontinuation of treatment with apremilast may be necessary   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10338 /201703 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                                                                 | 28/09/2017 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0015             | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                                      | 27/04/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/10338 /201609 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                                                                 | 06/04/2017 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0014/G           | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 08/03/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                        | 20/12/2016   | n/a        |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                        | 15/12/2016   | n/a        |             |                                                                                                                                            |
| PSUSA/10338 /201603 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                             | 13/10/2016   | 08/12/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10338/201603. |
| PSUSA/10338 /201509 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                             | 28/04/2016   | 08/07/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10338/201509. |
| IB/0009             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                        | 23/03/2016   | n/a        |             |                                                                                                                                            |
| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                            | 22/01/2016   | 08/07/2016 | SmPC and PL |                                                                                                                                            |
| IA/0006/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold | 30/10/2015   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10338 /201503 | Periodic Safety Update EU Single assessment - apremilast                                                                                                                                                                                                                                                                                                                                                                                               | 08/10/2015 | n/a | PRAC Recommendation - maintenance |
| IG/0590             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                        | 22/07/2015 | n/a |                                   |
| II/0003/G           | This was an application for a group of variations. Submission of non-clinical studies CC-10004-DMPK- 1965 and CC-10004-DMPK-1966 in fulfilment of MEA 001. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 11/06/2015 | n/a |                                   |
| IB/0002             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                         | 08/04/2015 | n/a |                                   |
| IA/0001             | B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                  | 13/03/2015 | n/a |                                   |